Weekly signal · AXSM · Healthcare

Axsome Therapeutics Inc (AXSM) extends its CNS-drug stock run

The weekly setup remains active, with improved market pressure offset by only moderate relative-strength confirmation.

Axsome Therapeutics Inc
Latest255.17 USD
1W move9.8%
Volume1.0x
TrendActive
Weekly market chart context for Axsome Therapeutics alongside CNS biotechnology research imagery.

Market update

What happened

Axsome Therapeutics Inc (AXSM) closed the latest week at 255.17 USD, up 9.8% for the week as the biotechnology stock continued to build on its recent advance.

The confirming evidence is constructive but not one-sided. Turnover was near normal at 3.44 million shares against a 3.48 million 13-week average, while Market Dynamics at 1.15 shows positive pressure and Relative Strength at 41.2 keeps confirmation measured in weekly context.

Continue your research

Explore AXSM across Sharemaestro

These links are shown because current Sharemaestro data is available for this company.

Interactive chartReview weekly price, Trend Line, Fair Value, volume and Relative Strength.Full weekly reportOpen the full company report, financial profile and peer comparison.Technical analysisExamine support, resistance, momentum and the current trend readings.Stage analysisSee whether the stock is basing, advancing, distributing or declining.Trend historyReview how long the current trend has persisted and where it has changed.Sector comparisonCompare sector returns, breadth, leaders and weaker areas.Industry comparisonSee how this company’s industry is performing across its members.Company factorsCompare value, quality, growth, momentum and financial strength.News sentimentSee the balance, quality and freshness of recent company coverage.Buying and selling pressureReview longer-term accumulation, distribution and reversal readings.EarningsReview report dates, estimates, past results and earnings surprises.Options activitySee options positioning, expected move and unusual trading activity.Short interestReview short positioning, crowding and possible squeeze risk.Insider transactionsSee reported purchases and sales by company directors and executives.

AXSM coverage

Evidence context